Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

NCT07343479 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
45
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Zhejiang Cancer Hospital

Collaborators